908 DEVICES INC (MASS) Stock News

Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue

It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.

Mentions: LRN ANIP CTGO

908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

908 Devices Announces Preliminary First Quarter 2025 Financial Results

New Strong Buy Stocks for April 1st

AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.

Mentions: VFC FOLD AFRM

Earnings Scheduled For November 12, 2024

Mentions: SILV SKYX XTNT HNRG ...

908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec Device

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Repligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains.

Mentions: RGEN

908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

908 Devices to Participate in Upcoming Investor Conferences

908 Devices to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook

908 Devices to Participate in Upcoming Investor Conferences

908 Devices to Report Third Quarter 2024 Financial Results on November 12, 2024

908 Devices to Participate in Craig-Hallum Bioprocessing Conference

MASS Stock Earnings: 908 Devices Misses EPS, Beats Revenue for Q2 2024

MASS stock results show that 908 Devices missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook

908 Devices to Participate in Canaccord Genuity 44th Annual Growth Conference

908 Devices to Report Second Quarter 2024 Financial Results on August 6, 2024

908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors

908 Devices to Participate in Upcoming Investor Conferences